Basic Information
ID DDInter2024 and DDInter1336
Interaction Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign intracranial hypertension. These agents individually have been associated with the development of pseudotumor cerebri and may have additive effects during coadministration. The interaction has been suspected in reported cases involving the use of isotretinoin or vitamin A in combination with a tetracycline. Other vitamin A-related compounds may interact similarly.
Management Coadministration of most retinoids with tetracyclines is considered contraindicated. Patients treated with a retinoid or a tetracycline should be advised to discontinue the medication and notify their physician immediately if they develop early symptoms of pseudotumor cerebri such as headache, nausea, vomiting, visual disturbances, vision loss, and papilledema. Although intracranial hypertension typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. Therefore, prompt ophthalmologic evaluation should be performed if visual disturbances occur. Since intracranial pressure may remain elevated for weeks after drug cessation, patients should be monitored until they stabilize.
References [1] Walters BN, Gubbay SS "Tetracycline and benign intracranial hypertension: report of five cases." Br Med J 282 (1981): 19-20 [2] Minutello JS, Dimayuga RG, Carter J "Pseudotumor cerebri, a rare adverse reaction to tetracycline therapy." J Periodontol 59 (1988): 848-51 [3] Delaney RA, Narayanaswamy TR "Pseudo-tumor cerebri and acne." Mil Med 155 (1990): 511 [4] Donnet A, Dufour H, Graziani N, Grisoli F "Minocycline and benign intracranial hypertension." Biomed Pharmacother 46 (1992): 171-2 [5] "Product Information. Achromycin (tetracycline)." Lederle Laboratories (2001): [6] Yokokura M, Hatake K, Komatsu N, Kajitani H, Miura Y "Toxicity of tretinoin in acute promyelocytic leukaemia." Lancet 343 (1994): 361-2 [7] Schmitt K, Schwarz R, Tulzer G, Krieger O, Zoubek A, Gadner H "Toxicity of tretinoin in acute promyelocytic leukaemia." Lancet 343 (1994): 361 [8] "Product Information. Accutane (isotretinoin)." Roche Laboratories (2001): [9] Gardner K, Cox T, Digre KB "Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review." Neurology 45 (1995): 6-10 [10] Cuddihy J "Case report of benign intercranial hypertension secondary to tetracycline." Ir Med J 87 (1994): 90 [11] Lee AG "Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne." Cutis 55 (1995): 165-8 [12] Roytman M, Frumkin A, Bohn TG "Pseudotumor cerebri caused by isotretinoin." Cutis 42 (1988): 399-400 [13] Lewis PA, Kearney PJ "Pseudotumor cerebri induced by minocycline treatment for acne vulgaris." Acta Derm Venereol 77 (1997): 83 [14] "Product Information. Soriatane (acitretin)." Roche Laboratories (2001): [15] Chiu AM, Chuenkongkaew WL, Cornblath WT, Trobe JD, Digre KB, Dotan SA, Musson KH, Eggenberger ER "Minocycline treatment and pseudotumor cerebri syndrome." Am J Ophthalmol 126 (1998): 116-21 [16] "Product Information. Vesanoid (tretinoin)." Roche Laboratories (2001): [17] Weese-Mayer DE, Yang RJ, Mayer JR, Zaparackas Z "Minocycline and Pseudotumor cerebri: The well-known but well-kept secret." Pediatrics 108 (2001): 519-20 [18] Moskowitz Y, Leibowitz E, Ronen M, Aviel E "Pseudotumor cerebri induced by vitamin A combined with minocycline." Ann Ophthalmol 25 (1993): 306-8 [19] Chan AY, Liu DT, Friedman DI, Gordon LK, Egan RA "Doxycycline and intracranial hypertension." Neurology 64 (2005): 765-6 [20] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 [21] Cerner Multum, Inc. "Australian Product Information." O 0 [22] Tabibian JH, Gutierrez MA "Doxycycline-induced pseudotumor cerebri." South Med J 102 (2009): 310-1 [23] "Product Information. Seysara (sarecycline)." Allergan Inc (2018):
Alternative for Etretinate D05B
Trioxsalen
Alternative for Omadacycline J01A
Tigecycline
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.